BAAR, Switzerland–(BUSINESS WIRE)–Stallergenes Greer, a world chief in allergy therapeutics, will current constructive outcomes from its SPEED survey on the upcoming CFA congress (Congrès Francophone d’Allergologie, the French congress of allergology) in Paris (France) April 15-18, 2025. The survey highlights each the impression of the iPUMP® linked assistant and its robust adoption amongst sufferers present process sublingual liquid allergen immunotherapy (SLIT) therapy.
iPUMP®, developed at the side of Aptar Digital Well being, helps adherence to Stallergenes Greer’s personalised SLIT remedies, by guaranteeing sufferers undertake the right dosing approach, period and frequency of therapy. This revolutionary and easy-to-use instrument is linked to a companion cell utility and offers direct entry to the therapy protocol prescribed to every affected person by their doctor.
The 2-step SPEED survey*, which measured the impression of the iPUMP® on affected person adherence and observance to SLIT therapy, confirmed a 15% improve in observance for sufferers utilizing iPUMP®.
Furthermore, for youngsters aged 5-12, parental involvement in therapy administration dropped from 50% to twenty-eight% over three months, whereas the proportion of youngsters independently taking their remedy rose from 24% to 58%. Notably, 90% of fogeys felt reassured by the linked assistant, with half feeling utterly comfy with therapy administration, in comparison with 36% within the non-iPUMP® group.
“Findings of the SPEED survey underscore the position of linked well being options in bettering each therapy adherence and affected person confidence, that are key components in attaining profitable therapeutic outcomes,” mentioned Elena Rizova, Chief Medical Officer. “Innovation is on the coronary heart of what we do and iPUMP®, by catering to the wants expressed by sufferers and healthcare professionals, meets their expectations and offers an answer to reinforce therapy administration and general allergy care.”
Marcus Bates, VP Enterprise Improvement & International Head of Respiratory at Aptar Digital Well being, commented, “The robust outcomes of the SPEED survey pave the best way for wider adoption of digital and linked options for allergy administration, enabling new sufferers to entry a easy, easy-to-use resolution that may assist observe adherence and keep engaged to realize higher well being outcomes.”
By integrating digital well being capabilities, Stallergenes Greer continues to drive ahead its mission to develop exact, patient-centric options which empower people and enhance therapy outcomes.
The outcomes of the SPEED survey set up a powerful basis for the broader adoption of iPUMP®, supporting Stallergenes Greer’s dedication to innovation for the advantage of sufferers, caregivers and the medical neighborhood.
ABOUT IPUMP®
iPUMP®, developed at the side of Aptar Digital Well being, is the primary linked assistant in allergology, designed for sufferers initiating sublingual liquid AIT therapy with Stallergenes Greer. Launched in February 2023 in France, it has been utilized by a complete of 9,097 sufferers up to now.
iPUMP® includes a linked stress sensor that converts the utilized drive into an audible sign as soon as the brink is reached, confirming the therapy consumption. An built-in timer marks the top of the every day dose in keeping with the prescription, and a light-weight indicator confirms the every day consumption.
Use by youngsters must be supervised by an grownup.
This revolutionary and easy-to-use instrument is linked to a companion cell utility and offers direct entry to the personalised therapy protocol prescribed by the physician.
iPUMP® helps help sufferers in bettering therapy adherence to optimise impression whereas providing a history-tracking operate for exact remedy monitoring.
ABOUT APTAR DIGITAL HEALTH
Aptar Pharma’s Digital Well being division is a part of AptarGroup, Inc., a world chief in drug and shopper product dosing, meting out and safety applied sciences. Aptar Digital Well being creates end-to-end options to reinforce affected person experiences on daily basis, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of merchandise and options, Aptar Digital Well being’s providing combines cell and net apps, Software program-as-Medical-Gadget, linked drug supply techniques, superior knowledge evaluation companies, and affected person onboarding and coaching options to actively empower sufferers and create a constructive therapy journey. Aptar is headquartered in Crystal Lake, Illinois and has greater than 13,000 devoted workers in 20 nations.
For extra info, go to www.aptardigitalhealth.com and www.aptar.com.
ABOUT STALLERGENES GREER
Headquartered in Baar (Switzerland), Stallergenes Greer is a world healthcare firm specialising within the prognosis and therapy of allergy symptoms by way of the event and commercialisation of allergen immunotherapy services. Supported by greater than 100 years of experience and innovation, our merchandise can be found for sufferers in over 40 nations.
For extra info, go to www.stallergenesgreer.com.
*SPEED real-life research (carried out by AplusA for Stallergenes Greer, carried out between 29 Might and 29 November 2024, based mostly on an internet questionnaire. The target was to measure the impression perceived by sufferers, after 3 months of therapy with AIT, with using the iPUMP® linked assistant. 104 paediatric sufferers aged over 5 years and 77 adolescent and grownup sufferers aged over 13 years).
Contacts
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
E-mail: catherine.kress@stallergenesgreer.com
BAAR, Switzerland–(BUSINESS WIRE)–Stallergenes Greer, a world chief in allergy therapeutics, will current constructive outcomes from its SPEED survey on the upcoming CFA congress (Congrès Francophone d’Allergologie, the French congress of allergology) in Paris (France) April 15-18, 2025. The survey highlights each the impression of the iPUMP® linked assistant and its robust adoption amongst sufferers present process sublingual liquid allergen immunotherapy (SLIT) therapy.
iPUMP®, developed at the side of Aptar Digital Well being, helps adherence to Stallergenes Greer’s personalised SLIT remedies, by guaranteeing sufferers undertake the right dosing approach, period and frequency of therapy. This revolutionary and easy-to-use instrument is linked to a companion cell utility and offers direct entry to the therapy protocol prescribed to every affected person by their doctor.
The 2-step SPEED survey*, which measured the impression of the iPUMP® on affected person adherence and observance to SLIT therapy, confirmed a 15% improve in observance for sufferers utilizing iPUMP®.
Furthermore, for youngsters aged 5-12, parental involvement in therapy administration dropped from 50% to twenty-eight% over three months, whereas the proportion of youngsters independently taking their remedy rose from 24% to 58%. Notably, 90% of fogeys felt reassured by the linked assistant, with half feeling utterly comfy with therapy administration, in comparison with 36% within the non-iPUMP® group.
“Findings of the SPEED survey underscore the position of linked well being options in bettering each therapy adherence and affected person confidence, that are key components in attaining profitable therapeutic outcomes,” mentioned Elena Rizova, Chief Medical Officer. “Innovation is on the coronary heart of what we do and iPUMP®, by catering to the wants expressed by sufferers and healthcare professionals, meets their expectations and offers an answer to reinforce therapy administration and general allergy care.”
Marcus Bates, VP Enterprise Improvement & International Head of Respiratory at Aptar Digital Well being, commented, “The robust outcomes of the SPEED survey pave the best way for wider adoption of digital and linked options for allergy administration, enabling new sufferers to entry a easy, easy-to-use resolution that may assist observe adherence and keep engaged to realize higher well being outcomes.”
By integrating digital well being capabilities, Stallergenes Greer continues to drive ahead its mission to develop exact, patient-centric options which empower people and enhance therapy outcomes.
The outcomes of the SPEED survey set up a powerful basis for the broader adoption of iPUMP®, supporting Stallergenes Greer’s dedication to innovation for the advantage of sufferers, caregivers and the medical neighborhood.
ABOUT IPUMP®
iPUMP®, developed at the side of Aptar Digital Well being, is the primary linked assistant in allergology, designed for sufferers initiating sublingual liquid AIT therapy with Stallergenes Greer. Launched in February 2023 in France, it has been utilized by a complete of 9,097 sufferers up to now.
iPUMP® includes a linked stress sensor that converts the utilized drive into an audible sign as soon as the brink is reached, confirming the therapy consumption. An built-in timer marks the top of the every day dose in keeping with the prescription, and a light-weight indicator confirms the every day consumption.
Use by youngsters must be supervised by an grownup.
This revolutionary and easy-to-use instrument is linked to a companion cell utility and offers direct entry to the personalised therapy protocol prescribed by the physician.
iPUMP® helps help sufferers in bettering therapy adherence to optimise impression whereas providing a history-tracking operate for exact remedy monitoring.
ABOUT APTAR DIGITAL HEALTH
Aptar Pharma’s Digital Well being division is a part of AptarGroup, Inc., a world chief in drug and shopper product dosing, meting out and safety applied sciences. Aptar Digital Well being creates end-to-end options to reinforce affected person experiences on daily basis, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of merchandise and options, Aptar Digital Well being’s providing combines cell and net apps, Software program-as-Medical-Gadget, linked drug supply techniques, superior knowledge evaluation companies, and affected person onboarding and coaching options to actively empower sufferers and create a constructive therapy journey. Aptar is headquartered in Crystal Lake, Illinois and has greater than 13,000 devoted workers in 20 nations.
For extra info, go to www.aptardigitalhealth.com and www.aptar.com.
ABOUT STALLERGENES GREER
Headquartered in Baar (Switzerland), Stallergenes Greer is a world healthcare firm specialising within the prognosis and therapy of allergy symptoms by way of the event and commercialisation of allergen immunotherapy services. Supported by greater than 100 years of experience and innovation, our merchandise can be found for sufferers in over 40 nations.
For extra info, go to www.stallergenesgreer.com.
*SPEED real-life research (carried out by AplusA for Stallergenes Greer, carried out between 29 Might and 29 November 2024, based mostly on an internet questionnaire. The target was to measure the impression perceived by sufferers, after 3 months of therapy with AIT, with using the iPUMP® linked assistant. 104 paediatric sufferers aged over 5 years and 77 adolescent and grownup sufferers aged over 13 years).
Contacts
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
E-mail: catherine.kress@stallergenesgreer.com
